MONTREAL, QUEBEC--(Marketwired - March 8, 2018) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Medimetriks Pharmaceuticals Inc. ("Medimetriks") has prepaid US$20 million of ...
more»